A ortic stenosis (AS) is the most common valvular disease, and the number of patients with AS is increasing with rapid aging of society. 1 Clinical symptoms and subsequent myocardial dysfunction 2, 3 have an important role in the risk stratification of patients with longstanding AS. The current guidelines 4, 5 designate a class I indication for aortic valve (AV) surgery in severe AS if symptoms or cardiac dysfunction, defined as resting left ventricular ejection fraction (LVEF) ≤50%, are present. LVEF is widely used as an objective marker of elevated cardiac risk. However, onset of impaired LVEF may represent an end stage of LV dysfunction and may be associated with permanent myocardial damage and worse outcomes even in those who receive intervention to correct AS 6 . Therefore, other objective parameters that might identify incipient LV dysfunction may be of prognostic and clinical value in AS patients with preserved LVEF.
Clinical Perspective on p 945
Several previous studies have suggested that LV-global longitudinal strain (LV-GLS) may detect subclinical LV dysfunction in patients with severe AS and help determine LV functional recovery post AV surgery. 7, 8 However, the incremental prognostic value of GLS was not well characterized in these studies because of the relatively small sample size. 9, 10 In addition, risk-stratification in patients with low-gradient severe AS (paradoxical severe AS) may be clinically challenging, especially as there are limited reports of outcome in these patients. 11 The aim of this study was to assess the utility of LV-GLS in Background-We sought to assess the utility of left ventricular global longitudinal strain (LV-GLS) in predicting mortality in moderate to severe and paradoxical severe aortic stenosis (AS) patients with preserved ejection fraction. Methods and Results-We studied 395 AS patients (70±14 years, 57% men) with aortic valve area <1.3 cm 2 evaluated between January to June 2008 (excluding severe other valve disease and LV ejection fraction <50%). Clinical and echocardiographic data were recorded. LV-GLS was analyzed using Velocity Vector Imaging. AS patients were classified as (a) moderate-severe (n=93; aortic valve area, 1.1-1.3 cm predicting mortality in moderate-severe, standard severe, and paradoxical severe AS patients with preserved LVEF.
Methods

Study Population
This was an observational cohort study of 395 consecutive patients with significant AS (aortic valve area [AVA] ≤1.3 cm 2 ), without severe tricuspid/mitral valvular disease, who had an echocardiogram at our tertiary care center between January 2008 and June 2008. We excluded patients who were determined to have a limited life expectancy because of noncardiac causes (ie, terminal malignancy, hemorrhagic stroke, and advanced lung disease) or death within 90 days of the incident echocardiogram without having undergone AV surgery (n=15), LVEF <50% (n=94), and those with unavailable digital imaging and communication in medicine (DICOM) data/poor image quality for strain assessment (n=22).
Clinical Data
Data were assembled by analysis of electronic medical records after appropriate approval by the Institutional Review Board. Demographics, clinical, and medication data were recorded. Presence of permanent atrial fibrillation was ascertained. Presence of an automated implantable cardioverter defibrillator and need for permanent pacemaker were recorded. The presence of angina, syncope, and New York Heart Association (NYHA) class was recorded to assess the symptomatic status of each patient.
The details of therapies were categorized as follows: (1) AV replacement (AVR), (2) AVR and coronary artery bypass grafting (CABG), (3) AVR and other valve repair or replacement±CABG, (4) AVR and ascending aorta repair or replacement±CABG, and (5) transcatheter AVR. The use of balloon aortic valvuloplasty was recorded. The remainder of the group was classified as having medical therapy. The decision to operate was made by the attending cardiothoracic surgeon and the cardiologist after a thorough clinical evaluation. In patients with severe AS (±obstructive coronary artery disease [CAD]), the decision regarding additional valve surgery (mitral/tricuspid valve repair) was made on an individual patient basis if concomitant moderate mitral/tricuspid valve disease was present. Based on the available preoperative data, additive Euro score was calculated to predict risk of postoperative mortality.
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Outcomes Assessment
All-cause mortality was considered to be the primary outcome. Death notification was confirmed by inspection of the death certificate or verified with a family member. The duration of follow-up ranged from the initial echocardiogram to June 2013.
Echocardiographic Data
All patients underwent a comprehensive echocardiogram with commercially available instruments (Philips Medical Systems, NA, Bothell, WA; General Electric Medical Systems, Milwaukee, WI; and Siemens Medical Solutions USA, Inc, Malvern, PA). Measurements and recordings were obtained according to guidelines. 13, 14 End-diastolic and end-systolic LV, interventricular septal and posterior wall thickness, and left atrial volume were measured from the 2-dimensional images and indexed to body surface area. LV mass was calculated and indexed to body surface area using the following formula: 1.04([LV end-diastolic dimension+posterior wall thickness+interventricular septal thickness]3-[LV end-diastolic dimension]3-13.6). LVEF was calculated using the Simpson's biplane method. Diastolic function was graded as normal, abnormal relaxation, pseudo normal, and restrictive filling. 15 We used a semiquantitative 5-point scale (none, mild, moderate, moderately severe, and severe) to stratify valvular regurgitation assessed by color 2-dimensional Doppler clips obtained in apical 2-and 4-chamber views. Right ventricular systolic pressure was estimated from the maximal continuous-wave Doppler velocity of the tricuspid regurgitant jet using systolic transtricuspid pressure gradient calculated by the modified Bernoulli equation and right atrial pressure. 16 All above measurements were taken from the original report.
For quantification of AS, LV outflow tract (LVOT) diameter was measured on parasternal long-axis views. Pulsed-wave and continuous-wave Doppler was used to record velocities across the LVOT and AV, respectively. LV stroke volume index (LV-SVI) was measured as LVOT VTI ×LVOT area /body surface area. A cutoff ≥35 mL/m 2 was considered as preserved LV-SVI. 14, [17] [18] [19] The assessment of AV was examined from multiple windows, including apical, suprasternal, and right parasternal to obtain the peak AV velocity and mean AV gradient. AVA was calculated using the continuity equation, and severe AS was defined as AVA ≤1 cm. 2 The patients were further classified as (a) moderate-severe AS (AVA 1.1-1.3 cm 2 ), (b) standard severe AS (AVA ≤1 cm, 2 mean gradient ≥40 mm Hg), and (c) paradoxical severe AS (AVA ≤1 cm2 and mean gradient <40 mm Hg). 17, 20 Finally, valvuloarterial impedance (mm Hg ml −1 m 2 ), a measure of global LV afterload, was calculated using the following formula 21 : mean AV gradient+systolic blood pressure/LV-SVI). All these parameters were remeasured for the present study.
Left Ventricular Global Longitudinal Strain
LV-GLS measurements were obtained from gray-scale images recorded in the apical 2, 3, and 4-chamber views. LV-GLS was analyzed offline using Velocity Vector Imaging (Syngo VVI, Siemens Medical Solutions, CA). After manual definition of LV endocardial border, the endocardium was automatically tracked throughout the cardiac cycle. Global LV strain was obtained by averaging segmental strain values from all 3 apical views. Peak global strain was defined as peak negative value on the strain curve during the entire cardiac cycle ( Figure 1 ). As mentioned before, we excluded patients where tracking quality (to calculate GLS) was inadequate in all segments. All measurements were made by an investigator blinded to clinical and demographic information and were performed and averaged over 3 cardiac cycles. If the patient had atrial fibrillation, all measurements were averaged over 5 cardiac cycles. The reproducibility of GLS, expressed as the coefficient of variation, has been described in detail by our group as 5.8% to 7.5% and 7.7% to 9.0% for intraobserver and interobserver variation.
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Statistical Analysis
Continuous variables are expressed as mean±SD and median and compared using analysis of variance (for normally distributed variables) or Mann-Whitney test (for non-normally distributed variables). Categorical data are expressed as percentage and compared using χ 2 . Association between continuous variables was tested using Spearman's correlation coefficient. To assess outcomes, Cox proportional hazards analysis was utilized. Initially, to understand the association between clinically relevant variables and survival, univariable analysis was performed. Subsequently, forward stepwise multivariable survival analysis was performed using relevant variables (associated with outcomes in AS patients), incorporating a P value threshold <0.1 as entry cutoff. AVR was included as a time-dependent covariate in Cox survival analysis. For each patient undergoing AVR, the analysis time was modeled so that only the person-time after AVR was included in the surgical group. The person-time before occurrence of AVR was included in the no-surgical category. Hazard ratios with 95% confidence intervals were calculated. To ensure proportional hazards assumption was not violated, graphical inspection of Schoenfield residuals plotted against time was performed. Also, to test the linearity of the relationship between LV-GLS and survival in the Cox Proportional Hazards model, we first inspected the scatterplot of martingale residuals (with LV-GLS in the model) against LV-GLS, using a Loess function. We also tested for nonlinearity after performing polynomial transformations of LV-GLS. Additionally, survival curves, adjusted for relevant predictors, were obtained as a function over time. Statistical analysis was performed using SPSS version 11.5 (SPSS Inc., Chicago, Illinois) and Stata version 10.0 (StataCorp, College Station, Texas). A P value of <0.05 was considered significant.
Results
Study Population
The baseline data are shown in Table 1 . Nearly one third patients had angina and two thirds were in NYHA class ≥II; with a significantly higher proportion of symptomatic patients having severe AS. Similarly, ≈46% patients in the study population had obstructive CAD, with increased prevalence in the severe AS subgroup. A high proportion of patients were on appropriate cardioprotective medications, with severe AS subgroups being on more therapy than those with moderatesevere AS. Additive Euroscore was also significantly different between moderate-severe and severe subgroups. The median Euroscore was 7 (interquartile range, 5-9).
The echocardiographic data are shown in Table 2 . Median GLS in the study population was −14.8% (interquartile range, −17.2%-12.1%). There was a small but significant difference in LV-GLS between the different AS subtypes. In the entire population, LV-GLS had a statistically significant but weak association with both LVEF (β=0.2; P<0.001) and indexed LV mass (−0.15, P<0.001).
In follow up, 246 (62%) underwent AVR, 71 (18%) AVR+CABG, 32 (8%) AVR+CABG+other valve surgery, 22 (6%) AVR+aortic surgery, and 12 (3%) transcatheter AVR. In addition, 2 (0.5%) patients had a balloon aortic valvuloplasty, whereas 147 (37%) were treated medically. Of note, there was no significant difference in LV-GLS in patients with and without obstructive CAD that also required concomitant CABG (−14.3±4% versus 15.1±4%, respectively; P=0.1). The relevant parameters of the study sample, divided on the basis of whether they underwent AVR versus medical therapy, are shown in Table I in the Data Supplement. The patients undergoing AVR had higher AV gradients, lower AVA, higher LV mass index, and a higher proportion of obstructive CAD, atrial fibrillation, and prior cardiac surgeries. Additionally, the proportion of patients with NYHA Class ≥II was much higher in the group undergoing AVR (as expected), but the mean additive Euroscores for the 2 groups were also similar. We subsequently performed Cox Proportional Hazard Survival analysis in the study population. Graphical inspection of Schoenfield residuals plotted against time revealed that proportional hazards model was not violated. Also, on inspection of the scatterplot of Martingale residuals (with LV-GLS in the model) against LV-GLS, no apparent trend was detected. Additionally, neither quadratic nor cubic transformations of LV-GLS were significant predictors of survival when forced into the Cox model that already included nontransformed LV-GLS. We initially tested the association between individual relevant predictors and mortality using Table 3 ). LV-GLS <−12.1% (4th quartile) was associated with significantly reduced survival (P<0.001). Additionally, incremental utility of symptom assessment, Euroscore calculation, and LV-GLS measurement to predict mortality was studied, as shown in Figure 3 . The χ 2 for the model that incorporated 3 variables (NYHA class, Euroscore, and LV-GLS) to predict mortality was significantly higher than the model that incorporated only NYHA class and Euroscore.
Outcomes and Survival Data
Discussion
In the present study of consecutive patients with moderatesevere and severe AS with preserved LVEF, we demonstrate that LV-GLS was predictor of mortality, independent of other known predictors. Additionally, AVR was significantly associated with improved survival when compared with medical therapy. To the best of our knowledge, this is one of the largest studies evaluating the incremental prognostic utility of LV-GLS in this population, in addition to known predictors like AV gradient, LV-SVI, 14, [17] [18] [19] and valvuloarterial impedance. 21 LV-GLS also provided incremental prognostic utility when added to a model based on clinical parameters (Additive Euroscore+NYHA class). The median LV-GLS in our study population was similar to a threshold for normal versus abnormal LV-GLS, as previously described in normal subjects. 24, 25 However, in the present study, AS patients with LV-GLS in the lowest quartile (<−12.1%) had a significantly higher mortality versus other quartiles despite a normal LVEF.
Of note, CAD or complexity of surgery did not significantly increase mortality. This is likely because the prevalence of obstructive CAD was much higher in the group that underwent AVR as compared with medical therapy (Table I in the Data Supplement). The fact that the majority of patients with obstructive CAD (and concomitant severe AS) got an AVR±CABG (which is a significant predictor of improved survival) might have superseded the adverse effect of CAD. Also, it is likely that significant survival advantage, accorded by AVR, superseded the increased risk of a combination surgical procedure.
The findings of our study are similar to previous reports that have demonstrated incremental utility of measurement of LV-GLS in the setting of significant AS. It has been identified as a predictor of recovery of postoperative LV dysfunction, 7 future AV surgery, 10 and all-cause mortality. 9 However, in the present study, the sample size was large with detailed characterization of AS subtypes. Also, unlike previous studies, the present study demonstrated incremental value of LV-GLS over LV-SVI and mean AV gradient.
In patients with AS, LV systolic pressure overload and wall stress are a direct consequence of LV remodeling. LV hypertrophy progresses to decrease wall stress and preserve systolic function. 26 However, there is eventual decline in LVEF, with resultant reduction in survival. Therefore, objective parameters are required to identify high-risk AS patients with preserved LVEF. Advanced parameters, like LV-GLS, are more sensitive in detecting subtle abnormalities in myocardial mechanics and may indicate pathology before this is evident on conventional indices of LV function. [27] [28] [29] Indeed, previous studies have demonstrated that impairment in LV-GLS can occur even in the setting of a preserved LVEF. In addition, patients with severe AS had significantly reduced LV-GLS compared with hypertensive patients with a similar degree of LV hypertrophy. 7 Another study has suggested that LV-GLS was a sensitive marker of myocardial fibrosis, which is increased in patients with severe AS versus hypertensive patients. 31 Whether the LV-GLS measurements, obtained using the current techniques, can be extrapolated to other available strain analysis software remains to be conclusively proven. However, an advantage of VVI software is that it is vendor-neutral. Indeed, a recent study has suggested that there is acceptable intersystem agreement, in terms of LV-GLS. 25 
Clinical Implications
In patients with preserved LVEF and moderate or severe AS, LV-GLS can potentially be used to predict mortality. Based on our study, AS patients, even in the setting of a preserved LVEF, are at a high risk for mortality in the setting of LV-GLS <−12.1%. Assessment of LV-GLS provides a cheap and noninvasive tool that can aid in improved risk stratification of AS patients, over and above standard clinical parameters, including symptom status and preoperative risk scores. In addition, offering AVR in such patients significantly improves survival compared with medical therapy.
Limitations
This was an observational retrospective study conducted at a large tertiary care center and is likely not free from referral bias. However, LV-GLS measurements were made in a blinded fashion in each patient after the initiation of the present study. Velocity vector imaging is vendor-independent strain software that is relatively easy to use, but its clinical utility remains unproven. Also, cutoffs of normal versus abnormal LV-GLS values may vary with different analysis software, and hence, the results may not be generalizable across imaging platforms. Further study is needed to replicate these findings prospectively and to determine whether intervention on the basis of reducing LV-GLS may positively affect long-term survival. We do not have data on specific extent of CAD in the entire study population. We report all-cause mortality, as opposed to cardiac mortality.
Conclusions
In patients with preserved LVEF and moderate or severe AS, LV-GLS is a strong and independent predictor of mortality. LV-GLS could have a potential role in risk stratification in such patients, in addition to symptom assessment. Asymptomatic patients with an abnormal LV-GLS fare significantly worse with medical therapy compared with AVR, even in the setting of a preserved LVEF. Future prospective studies need to confirm this interesting observation.
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